Publications and Abstracts

Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. (2019) Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer. JAMA Network Open 2:e1917062 – View Abstract


Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, et al. (2019) Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. Journal of Thoracic Oncology 14:1223. – View Abstract


Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58. – View Abstract


Dormady S, Broder MS, Putcha GV, Dumanois RH, DeCristofaro AH, et al. (2015) The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol 20:59. – View Abstract


Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, et al. (2014) Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small cell lung cancer. Clinical Lung Cancer 15:426.View Abstract


Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, et al. (2013) Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagnostic Molecular Pathology 22:65. – View Abstract


Kratz JR, He J, Van Den Eeden SK, Zhu Z, Gao W, et al. (2012) Kratz JR, Van Den Eeden SK, He J, Jablons DM, Mann MJ. (2012) A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA 308:1629. – View Abstract


Kratz JR, He J, Van Den Eeden SK, Zhu Z, Gao W, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823. – View Abstract


Mann M, Jablons D, O’Day K, Su W, Sundar P. (2020, May). The potential of a CLIA-certified prognostic/predictive molecular test to address the rising costs of non-small cell lung cancer. Journal of Clinical Oncology. 38 supplement:e21671. – View Abstract


Hamilton B, Haro G, Woodard G, Sheu B, Kratz J, et al. (2020, May) Everybody must get scanned? Molecular risk stratification may limit the need for CT surveillance following surgical resection of early-stage non-squamous, non-small cell lung cancer. Abstract presented at ATS International Conference, Philadelphia, PA. – View Abstract


Woodard G, Wang S, Kratz J, Haro G, Gubens M, et al. (2018) Expanded data confirm molecular testing identifies lung adenocarcinoma patients, including stage IA, who benefit from adjuvant chemotherapy. Journal of Thoracic Oncology. 12:s835. – View Abstract


Haro G, Kratz J, Cook N, He J, Van Den Eeden G, et al. (2018) Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. Journal of Thoracic Oncology. 13:s919. – View Abstract


Woodard G, Crockard J, Zoon-Besselink C, Kratz J, Gubens M, et al. (2017) Adjuvant chemotherapy decisions based on molecular risk status improves outcomes in early stage, non-small cell lung cancer. Journal of Thoracic Oncology. 12:s320. – View Abstract